Division of Cardiothoracic Surgery, Beth Israel Medical Center, New York, NY.
Division of Cardiothoracic Surgery, Beth Israel Medical Center, New York, NY.
J Thorac Cardiovasc Surg. 2014 Jan;147(1):133-40. doi: 10.1016/j.jtcvs.2013.08.040. Epub 2013 Oct 5.
We sought to determine if the radial artery (RA) or the free right internal thoracic artery (RITA) is the better conduit to bypass the circumflex coronary artery during coronary artery bypass grafting (CABG) using the left internal thoracic artery (LITA).
Propensity matching was performed on 2488 CABG-LITA patients from 2 affiliated centers, resulting in 528 pairs who received either a RA at one center or a free RITA at the other center to bypass the circumflex coronary artery from 1995 to 2009.
Kaplan Meier estimated 1-, 5-, 10-, and 15-year survival rates were 99%, 95%, 85%, and 76% for RA patients, respectively, and 97%, 92%, 80%, and 71% for RITA patients, respectively (P = .060). Major adverse events (MAEs) were fewer in the RA group (7.6% vs 14.0%; P = .001) and use of the RA was a significant predictor of reduced MAEs (odds ratio [OR], 0.48; P = .002) in all patients and especially in diabetic (OR, 0.32; P = .003), older (OR, 0.40; P = .009), obese (OR, 0.15; P < .001), and chronic obstructive pulmonary disease (COPD) (OR, 0.05; P = .016) patients. However, survival was better with RA only in COPD (hazard ratio, 0.49; P = .045) and older (hazard ratio, 0.71; P = .050) patients. Overall RA patency (83.9%) was similar to RITA patency (87.4%) at a mean of 5.1 ± 3.8 years (P = .155).
Long-term survival is similar in CABG-LITA patients using either a RA or free RITA graft to bypass the circumflex coronary artery. RA grafting has fewer MAEs, a similar patency to RITA, and improves survival in older and COPD patients. The choice of the second arterial conduit should be guided by patient profiles and surgeon preferences.
我们旨在确定在左胸廓内动脉(LITA)冠状动脉旁路移植术中,桡动脉(RA)或游离右胸廓内动脉(RITA)作为旁路回旋支冠状动脉的更佳血管。
对来自 2 家附属医院的 2488 例 LITA-CABG 患者进行倾向评分匹配,结果产生了 528 对患者,其中 1995 年至 2009 年期间,1 家中心采用 RA,另 1 家中心采用游离 RITA 来旁路回旋支冠状动脉。
Kaplan-Meier 估计 RA 组患者 1 年、5 年、10 年和 15 年的生存率分别为 99%、95%、85%和 76%,RITA 组患者分别为 97%、92%、80%和 71%(P=0.060)。RA 组的主要不良事件(MAE)较少(7.6% vs 14.0%;P=0.001),并且在所有患者中,RA 的使用是 MAE 减少的显著预测因子(优势比[OR],0.48;P=0.002),尤其是在糖尿病(OR,0.32;P=0.003)、年龄较大(OR,0.40;P=0.009)、肥胖(OR,0.15;P<0.001)和慢性阻塞性肺疾病(COPD)(OR,0.05;P=0.016)患者中。然而,只有在 COPD(风险比,0.49;P=0.045)和年龄较大(风险比,0.71;P=0.050)的患者中,RA 的生存获益更好。在平均 5.1±3.8 年时,RA 通畅率(83.9%)与 RITA 通畅率(87.4%)相似(P=0.155)。
在使用 LITA-CABG 旁路回旋支冠状动脉时,使用 RA 或游离 RITA 移植物的患者,其长期生存率相似。RA 移植物的 MAE 较少,通畅率与 RITA 相似,并且可改善年龄较大和 COPD 患者的生存率。第二根动脉移植物的选择应根据患者的具体情况和外科医生的偏好来指导。